NuCana shares see a dip: what is pressuring the stock

Traders Union
All News
Financial News
Nucana slides 2.92% today to $1.66

Highlights

NuCana reported a £29.4 million loss for 2025, forecasting its £24.3 million cash balance can support operations for about twelve months.
The company eliminated remaining Series A Warrants for $3.6 million post-capital raise and disclosed further clinical advancements in its melanoma program.
NCNA trades under persistent selling pressure with key resistance at $1.95 and a bearish outlook as downside risk dominates the 5-day range near $1.59–$1.63.

Broad selling persists despite fundraising and clinical milestones

NuCana reported a loss of £29.4 million for 2025, with £24.3 million in cash and cash equivalents expected to fund operations for about twelve months. The company canceled its remaining Series A Warrants from its May 2025 financing in exchange for $3.6 million in payments, following a successful capital raise. Further clinical progress was recorded with NUC-7738 in melanoma and a Form 3 was filed by the Chief Medical Officer disclosing his option grants and shareholdings, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that NCNA’s sharp underperformance across all major moving averages highlights sustained technical weakness. He points out that heavy losses and limited cash reserves add fundamental pressure, while warrant cancellations and ongoing selling hint at low investor confidence. Kharitonov believes even oversold conditions do not guarantee a rebound with such downbeat sentiment and negative news flow. Risk of further downside remains high if $1.59 fails to hold. "Given the current setup, I see little justification for exposure here until both technical and fundamental headwinds ease significantly."

Viktoras Karapetjanc, expert at Traders Union, sees opportunity in NCNA’s recent decisive funding moves and continued clinical progress. He believes the company’s proactive capital raise and efficient use of cash extend operational flexibility despite a challenging year. Karapetjanc highlights that advances with NUC-7738 may reawaken investor interest, keeping the bullish long-term structure intact. "While near-term weakness persists, I am confident this market offers setups for forward-looking buyers as NuCana advances its science."

Parshwa Turakhiya, analyst, notes the stock’s rapid slide has driven momentum and sentiment indicators into oversold territory. He sees short-term traders watching for a technical bounce if support near $1.59 holds, but warns that any recovery faces immediate resistance at $1.95. Turakhiya maintains a scenario-based view, awaiting confirmation from price action before committing either way. "Traders should stay nimble and let intraday sentiment and volatility shape short-duration opportunities around these key levels."

Oversold signals intensify as technical barriers reinforce bearish momentum

The current price of NCNA ($1.66) is trading well below the short-term SMA-20 ($2.02), as well as the mid-term SMA-50 ($2.48) and long-term SMA-200 ($5.87), highlighting persistent downward pressure across all relevant timeframes. Immediate dynamic resistance is indicated by the Ichimoku Kijun level at $1.95, with no major dynamic support above the current price. Momentum signals remain weak: MACD, ADX, and AO all favor sellers, and RSI has dipped under 30, confirming an oversold setup that is echoed by CCI and Stoch RSI. BBP indicates sellers have the upper hand in intraday action. The stock slipped 2.92% today, with no noticeable gap at the open. Price currently trades near the low end of the intraday range after moderate volatility, suggesting ongoing pressure after the open. There is clear alignment between intraday weakness and dominant bearish momentum signals; no significant conflicts are observed among the oscillators.

Earlier, analysts noted that NuCana shares remained under sustained technical pressure with strong bearish momentum dominating across multiple timeframes. The current analysis not only reaffirms this negative bias but adds that a decisive move below $1.59 would indicate a renewed wave of downside risk for NCNA in the immediate term.

Source of Data: NCNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.